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[57] ABSTRACT
Thermochemiluminescent complexes of an adaman-
tylideneadamantane 1,2-dioxetane and a cyclodextrin
are non-volatile at the temperatures used to excite the
thermochemiluminescence. The complexes can be en-
capsulated in immunosensitized microcapsules, e.g.,
liposomes, to provide a labeled immunoreagent useful
in immunoassay using thermochemiluminescent
labeled immunoreagents.
9 Claims, 3 Drawing Sheets
U.S. Patent Jun. 19, 1990 Sheet 1 of 3 4,935,407
U.S. Patent Jun. 19, 1990 Sheet 2 of 3 4,935,407

















This invention relates to thermochemiluminescent
cyclodextrin complexes and more particularly to ther-
mochemiluminescent complexes of an adaman-
tylideneadamantane 1,2-dioxetane and a cyclodextrin
which are useful as labels in immunoassays.
Thermochemiluminescent compounds are those which
upon heating, generally to a temperature above room
temperature, undergo a chemical reaction which results
in the emission of luminescence. Generally, compounds
of this type undergo a thermally induced decomposition
or rearrangement which yields a product in an electronic
excited state capable of undergoing a radiative transition
to a ground state with emission of luminescence.
A particular class of thermochemiluminescent com-
pounds having utility in the field of immunoassay are
the adamantylideneadamantane 1,2-dioxetanes, which
undergo a thermochemiluminescent internal reaction
upon heating to a temperature of about 240° C. In order
to prepare a labeled immunoreagent capable of thermo-
chemiluminescence, the adamantylideneadamantane
1,2-dioxetane nucleus is substituted with an organic
radical which is capable of reacting with an immunorea-
gent, e.g., an antigen or antibody, to form a covalently
linked labeled immunoreagent. The labeled immunorea-
gents can then be used in a conventional immunoassay.
A thermochemiluminescent immunoassay is thereby
possible wherein an immunoreagent labeled with a ther-
mochemiluminescent substituent forms a complex with
a complementary immunoreagent to yield a labeled
immunocomplex which can be separated from the rea-
gents, e.g., by precipitation or adsorption onto a solid
support. The immunocomplex so formed can be quanti-
tated by heating to stimulate the thermochemilumines-
cence of the label and measuring the amount of light
emitted by the heated immunocomplex.
In an alternative embodiment, the thermochemilu-
minescent label may be encapsulated within a microcap-
sule, e.g., a liposome, which bears on its surface an
immunoreagent. In an immunoreaction, the microcap-
sule, dispersed in an aqueous medium, becomes bound
to a complementary immunoreagent in the medium to
form an immunocomplex which is then separated from
the medium by conventional means such as centrifuga-
tion, filtration or the like. The separated immunocom-
plex is then heated to excite the thermochemilumines-
cent compound and the amount of immunocomplex
present is determined by measuring the amount of light
emitted by the luminescent complex. The amount or
concentration of unknown labeled immunocomplex is
then determined in the conventional manner by com-
parison of the intensity of the luminescence with that of
a series of standards of known amount or concentration.
However, a problem arises in thermochemilumines-
cent analyses using the adamantylideneadamantane 1,2-
dioxetanes when the thermochemiluminescent label is
not covalently bound to the immunoreagent, e.g., when
the label is encapsulated in an immunosensitized micro-
capsule, e.g., a liposome. The adamantylideneadaman-
tane 1,2-dioxetanes are appreciably volatile at the rela-
tively high temperatures, e.g., 240° C., used to excite
the thermochemiluminescence. When these compounds
are covalently bound to a non-volatile immunoreagent,
volatilization is prevented, but when the thermo-
chemiluminescent compounds are merely contained in
microcapsules, e.g., liposomes, they may be able to
volatilize as the temperature is raised if the microcap-
sules themselves are ruptured upon heating. This is
evidently a danger when microcapsules containing
aqu ous solutions are heated to temperatures above the
boiling point of water, and is especially a problem with
liposomes whose walls are merely fragile lipid mem-
branes. The volatilized compounds are lost and, as a
result, their luminescence is not detected and the mea-
su ement will be inaccurate.
Accordingly, a need has continued to exist for a.
means of increasing the accuracy of thermochemilu-
minescent immunoanalyses particularly when micro-
capsules are used as immunoreagents.
The problem of excessive volatility has now been
solved by a method of thermochemiluminescent im-
munoanalysis using as the thermochemiluminescent
label a novel complex of an adamantylideneadaman-
tane 1,2-dioxetane with a cyclodextrin. According to
the nvention, a complex of a cyclodextrin and an ada-
mantylideneadamantane 1,2-dioxetane is encapsulat d
in a icrocapsule having on its surface an immunorea-
gent. The microcapsule so sensitized is then suspended
in  aqueous solution and a complementary immuno-
reagent is mixed with the microcapsule suspension,
whereby an immunocomplex of the sensitized micro-
capsule and complementary immunoreage t is formed.
The immunocomplex is then separated from the solu-
tion and heated to a temperature at which the thermo-
chemiluminescent reaction of the label is excited. The
emitted light is quantitated and the amount of immuno-
complex present is determined in the conventional way
by comparison with a standard.
Accordingly, the present invention is concerned with
a thermochemiluminescent complex of an adaman-
tylid neadamantane 1,2-dioxetane and a cyclodextrin
and a process for the preparation of said complex.
A further object of the invention is a method for
i m noanalysis using this complex.
A further object is to provide a method of immuno-
assay using a thermochemiluminescent compound en-
capsulated in a microcapsule.
The Figures accompanying the present patent appli-
cation show the following data:
FIG. 1A shows the chromatogram of a thermo-
chemiluminescent complex of the invention.
FIG. 1B shows the chromatogram of a solution con-
taining only the thermochemiluminescent compound of
Formula I.
FIG. 1C shows the chromatogram of a solution con-
taining only gamma-cyclodextrin.
FIG. 1D shows the chromatogram ofN-hydroxysuc-
cinimide.
FIG. 2 shows a plot of chemiluminescence versus
amount of the thermochemiluminescent complex of the
inv ntion (in a double logarithmic scale).
FIG. 3 shows a plot of chemiluminescence versus
mount of thermochemiluminescent complex of the
invention when the complex of the invention is encap-
sulated in a liposome (in a double logarithmic scale).
The thermochemiluminescent compounds of this
invention are complexes of an adamantylideneadaman-
tane 1,2-dioxetane and a cyclodextrine. Cyclodextrins
are cyclic oligosaccharides obtained by the action of
Bacillus macerans on starch to form homogeneous
cyclic alpha-(1-4) linked D-glucopyranose units. Three












beta- and gamma-cyclodextrin, and having rings com-
prising 6,7 and 8 glucose residues respectively. The
preferred cyclodextrins for use in this invention are
beta- and gamma-cyclodextrin. Gamma-cyclodextrin is
the most preferred cyclodextrin.
In the present patent application the wording cy-
clodextrin is meant to include chemically modified cy-
clodextrin or cyclodextrins containing functional groups
like the p-toluenesulfonyl-, azido-, halogen-,
mesitylenesulfonyl-, perbenzoyl-, amino-, alkyl- or alk-
oxy groups. The cyclodextrin may be aminated, to e.g.
cyclodextrin-(OC2H4NH2)n, -(NH2)n or -(NCH3(CHO))n,
be esterified, to e.g. cyclodextrin-(ONO2)n, -(OSO3H)n,
-(OPO3H2)n, -(OCOC6H5)n or -(OCOCH3)n, be
etherified, to e.g. cyclodextrin-(OCH3)n, -
(OCH2CO2Na)n or -(OCH2CHOHCH2OH)n or be
methylated.
In the above formulas n may vary from 1 to the num-
ber of groups in the cyclodextrin molecule which are
able to be substituted by the groups given above. These
chemically modified cyclodextrins or these cyclodex-
trins comprising functional groups are known in the art
and-as such-do not form part of the present invention.
The adamantylideneadamantane 1,2-dioxetanes use-
ful according to this invention include compounds of
the formula:
wherein R1 is selected from the group consisting of H,
Cl, Br, F, I, OH, NH2, OR
2 and NHR2 wherein R2 is an
aliphatic organic radical containing no more than 20
carbon atoms. It will be evident to those skilled in the
art that since the thermochemiluminescence of these
molecules is due to the adamantylideneadamantane
1,2-dioxetane portion of the molecule, the exact nature
of the substituent R1 is not of great importance. It must
not interfere with the thermochemiluminescent proper-
ties of the molecule, but, since the thermochemilumines-
ce t center is somewhat remote from the substituent R1,
this condition is not difficult to satisfy. Accordingly, a
wide range of substituents R1 i  possible. Besides the
unsubstituted molecule wherein R1 is H, R1 may be a
substituent such as halo, hydroxy or amino. Alterna-
tively, R1 may be an alkoxy or substituted amino group
of the formula -OR2 or -NHR2 respectively, wherein R2
is an aliphatic organic radical having a straight or
branched chain of carbon atoms from C1 to and includ-
ing C20. R
1 may also be an ester or amido group of the
formula -OR2 or -NHR2 respectively, wherein R2 is an
acyl group containing up to 20 carbon atoms. Sub-
stituents R1 containing functionally substituted groups
R2 are also useful, as well as those wherein one or more
of the carbon atoms in the chain is replaced by an oxy-
gen or nitrogen. In particular, omegasubstituted radicals
may b  used which have at the distal end of the radical a
functional group capable of reacting with a protein.
Such groups include mixed anhydrides, active esters,
active carbonyl groups, and the like groups capable of
reacting with the amino groups of proteins. Thus, the
substituents R2 may include C1- 20 aliphatic hydro-
carbon groups such as methyl, ethyl, hexyl, decyl, stea-
ryl, and arachidyl; aliphatic acid residues, such as acetyl,
propanoyl, hexanoyl, lauroyl, stearoyl, and the like;
aliphatic acid radicals having functional groups such as
3-hydroxy-propanoyl, 2-hydroxypropanoyl, and the like.
The substituent R1 must not interfere with the formation
of the complex of the adamantylideneadama t ne 1,2-
dioxetane with cyclodextrin by reason of its steric or
other properties. In particular, very bulky groups such as
protein molecules and the like interfere with the
formation of the complex and such groups are not
preferred for substituents R1. It has also been found that
the substituted adamantylideneadamantane 1,2-
dioxetanes wherein substituent R1 is a relatively small
group are better suited to form complexes with beta-
cyclodextrin, whereas those compounds having larger
substituents R1 will only form useful complexes with
gamma-cyclodextrin. In general the complexes with
gamma-cyclodextrin are preferred.
Particularly preferred substituted adaman-













The general preparation of the optionally substituted
adamantylideneadamantane 1,2-dioxetanes used in pre-
paring the thermochemiluminescent complexes of the
invention is conventional and forms no part of this in-
vention. Preparation of substituted adamantylideneada-
mantanes is disclosed in Meijer, E. W., et al., J. Org.
Chem. 47, 2005 (1982). A general method for preparing
the adamantylideneadamantane 1,2-dioxetanes is dis-
closed in Wieringa, J.H., et al., Tetrahedron Letters
1972, p. 169.
To prepare the thermochemiluminescent complexes
of the invention the adamantylideneadamantane 1,2-
dioxetane is contacted with the cyclodextrin in a suit-
able solvent. Since the compounds of formula I are
relatively slightly soluble in water, while the cyclodex-
trins are soluble in water, the complexes are generally
prepared by dissolving the compound of formula I in a
water-miscible organic solvent and mixing this solution
with an aqueous solution of the cyclodextrin. Suitable
water-miscible organic solvents include dioxan, lower
aliphatic alcohols such as ethanol, acetone, and 1,2-
dimethoxyethane. A preferred water-miscible solvent
for the adamantylideneadamantane 1,2-dioxetanes is
dioxan.
The concentrations of thermochemiluminescent com-
pound and of cyclodextrin should preferably be chosen
to provide a large molar excess of cyclodextrin. The
complexes are generally prepared by mixing a solution
of a thermochemiluminescent compound in a water-
miscible solvent and a solution of a cyclodextrin in
water, although preparation by dissolving the thermo-
chemiluminescent compound in an aqueous solution of
cyclodextrin is not excluded. When the complexes are
prepared by mixing solutions of the ingredients, the
relative volumes used may vary widely. For example
the complexes may be prepared by mixing approxi-
mately equal volumes of a solution of the thermo-
chemiluminescent compound in a water-miscible sol-
vent and an aqueous solution of cyclodextrin. Alterna-
tively, the thermochemiluminescent compound may be
dissolved in a relatively small amount of water-miscible
solvent and this solution can be mixed with a relatively
large amount of an aqueous solution of cyclodextrin.
The concentrations of the solutions are chosen to pro-
vide at least an equimolar amount of cyclodextrin and
thermochemiluminescent compound. However, in order
to maximize the amount of thermochemiluminescent
complex formed, it is preferred that the cyclodextrin be
in substantial molar excess, e.g., a molar ratio of
cyclodextrin to adamantylideneadamantane 1,2-dioxe-
tane of 10:1 or greater, more preferably 20:1 or greater.
The concentration of the adamantylideneadamantane
1,2-dioxetane in the water-miscible organic solvent may
vary between wide ranges, e.g. from 0.001 mg/ml to 100
mg/ml, or even greater. A low concentration is used
when the amount of solution of thermochemilu-
mi escent compound is equal to or not much less than
the volume of the aqueous cyclodextrin solution, while a
high concentration is used when a relatively small
amount of solution of the thermochemiluminescent
compound is mixed with a substantially greater amount
f aqueous cyclodextrin solution. The molar concentra-
tion of the cyclodextrin in the complex-forming solutio
should be substantially greater than that of the
her ochemiluminescent compound. A concentration of
1 mg/ml of cyclodextrin in water is a convenient
conc ntration and it may be even higher, up to a satu-
rated aqueous solution. Typically, the adaman-
tylideneadamantane 1,2-dioxetane is prepared as a solu-
tion in dioxane containing about 10 mg/ml (20 millimo-
lar) and is mixed with about 20 volumes of an aqueous
solution of cyclodextrin having a concentration of about
26 mg/ml (2o millimolar) to form the complex.
It is preferred to use the thermochemiluminescent
complexes of this invention as reporter molecules in
immunoassays using immunosensitized microcapsules,
.g., liposomes, as the immunoreagents. Such immuno-
as ays are known and are disclosed, for example, in
U mura, K., et al., Biochemistry 11, 4085-4094 (1972),
K taoka, T., et al., Biochimica et Biophysica Acta 298,
















Kakimi et al., U.S. Pat. No. 4,342,739. According to this
invention, thermochemiluminescent complexes are en-
capsulated in immunosensitized microcapsules which
are then used in the conventional manner to perform an
immunoassay, e.g., by reaction with a complementary
immunoreagent to produce precipitated immunocom-
plex, separation of the precipitate and quantitation of the
separated immunocomplex. When the sensitized
microcapsules contain a thermochemiluminescent com-
plex of this invention, the separated precipitated lipo-
some immunocomplex is placed in the heating chamber
of a conventional thermochemiluminescence analyzer,
heated to excite the chemiluminescence and the emitted
luminescence is measured to obtain a quantitative esti-
mate of the amount of immunocomplex.
The use of the thermochemiluminescent compounds
of the invention in microcapsules has the advantage that
it is possible to maintain a relatively high concentration
of thermochemiluminescent compound and cyclodextrin
within the liposome and thereby maintain the complex
in the associated form. Since the association constant of
the complex is about 104-105, the complexes tend to
dissociate at the extreme dilutions used in immu-
noassays. However, when the reagents are encapsulated
in microcapsules the concentration of thermochemilu-
minescent reagent and cyclodextrin can be high enough
to keep most of the material in the complexed form.
The microcapsules containing the thermochemilu-
minescent compounds of this invention may be prep red
by conventional procedures such as coacervation,
interfacial polymerization and the like. The formation f
microcapsules is disclosed, for example, in Mi-
croencapsulation Processes and Applications, Jan E.
Vandegger, Ed., Plenum press, 1974. Binding of im-
munoreagents, e.g., antigens or antibodies, to the sur-
face of the microcapsules is disclosed, for example, in
Kakimi et al., U.S. Pat. No. 4,342,739.
The following examples will illustrate the invention
but are not intended to be limiting.
EXAMPLE 1
This example illustrates the preparation of a complex
of gamma-cyclodextrin and an adamantylideneadaman-
tane 1,2-dioxetane of the invention.
A solution, containing 5 milligrams of the compound
of Formula II in 50 microliters of dioxane, was pipetted
into one milliliter of an aqueous 20 mM borate buffer
solution (pH 8.5), containing 2 milligrams of cyclodex-
trin. The molar ratio of the compound of Formula II to
gamma-cyclodextrin was thus about 5:1. The complexes
were then separated from the reagents by column chro-
matography on a column of cross-linked dextran (Se-
phadex LH60) 20 cm long ´ 2.5 cm diameter, using a
20 mM borate buffer (pH 8.5). The chromatograms ob-
tained are illustrated in FIG. 1, wherein the amount of
material in each fraction of eluate collected was de-
tected by properties appropriate to its chemical nature.
FIG. 1A shows the chromatogram of the complex, while
FIG. 1B shows the chromatogram of a solution
containing only the thermochemiluminescent compou d
of Formula II. The materials were detected by their
thermochemiluminescence. Measurements performed
on an Al2O3 thin layer chromatography sheet (Merck)
are given as a continuous line in FIGS. 1A and 1B,
while measurements performed on Kapton 500M ®,
manufactured by E.I. duPont de Nemours and Co., are
given as a dotted line. FIG. 1C shows the chromatogram
of a solution containing only gamma-
cyclodextrin (g-CD), wherein the amount of gamma-
cyclodextrin in each fraction collected was determined
by measuring the activity of the gamma-cyclodextrin by
the method of Vikman (Vikman, M., I. Int. Symp. on
Cyclodextrins, Budapest 1981, ed. J. Szejtli, pp. 69-74).
FIG. 1D illustrates the chromatogram of N-hydrox-
ysuccinimide, a hydrolysis product of the compound of
Formula II, wherein the amount of N-hydroxysuccini-
mide in each fraction collected was determined by mea-
sur ng the optical absorbance of the solution as a wave-
length of 280 nm (E280).
EXAMPLE 2
Thi  example illustrates the excellent linearity and
reproducibility obtainable with the thermochemilu-
minescent compounds of this invention and their lack of
vola ility at the temperatures used to excite the lumines-
cence.
A thermochemiluminescence (TCL) complex was
formed by the procedure of Example 1 and purified by
chromatography over a cross-linked dextran gel (Se-
phadex LH60, 40-120 micron) column. A series of dilu-
tions of the complex was prepared using 15 millimolar
gamma-cyclodextrin solution as a diluent to prevent
dissociation of the complexes. Samples of each of the
dilutions were analyzed by a conventional thermo-
chemiluminescent procedure. A drop of each sample was
placed on a thin disk of a polyimide resin (Kapton 500M
®, manufactured by E.I. duPont de Nemours & Co.) and
the sample so prepared was placed in the oven of a
conventional thermochemiluminescence analyzer where
it was heated to a temperature of 240° C. The intensity of
the luminescence emitted by the heated sample is
monitored by a photodetector, e.g., a multiplier
phototube, whereby an electrical signal proportional t
th  intensity of the luminescence is generated. The signal
is integrated over the heating time so that the integrated
signal represents the total amount of luminescence
emitted by the sample. The results are presented in FIG.
2 wherein the total number of counts representing quanta
emitted (TCL counts/sample) is plotted against the
number of moles of the compound of Formula II in the
s ple. Each point represents the average of six
determinations. The coefficient of variation for each
poi t was between 1.4% and 3.1 %. (The coefficint of
variation was corrected at low concentrations for
counting statistics.) It can be seen from the plot that the
lin arity is excellent (correlation coefficient of linear
regression r=0.9998), which indicates that none of the
th rmochemiluminescent compound is evaporating and
being lost.
EXAMPLE 3
This example illustrates the preparation of liposomes
containing the complex of adamantylideneadamantane
1,2-dioxetane and gamma-cyclodextrin.
The solution of Example 1 was encapsulated in lipo-
som s by a conventional sonification procedure. Thirty-
hree micromoles of cholesterol and 33 micromoles of
lecithin were dissolved in 2 milliliters of a mixed solvent
of chloroform and methanol (volume ratio 1:1), and the
solution was placed in a 50 milliliter round bottom flask
and subjected to rotary evaporation until all solvent had
been evaporated, leaving a coating of the solute on the
walls of the flask. One milliliter of the solution prepared
in Example 1 was added to the flask and the flask was
subjected to ultrasonic vibration in a waterbath for one
















was subjected to exclusion column chromatography on a
column of polyacrylamide gel beads (Sephacryl s300) in
order to separate the liposomes from the solution
containing unencapsulated reagents.
EXAMPLE 4
This example illustrates the thermochemilumines-
cence of the liposome-encapsulated complexes of this
invention.
A dilution series of the liposomes prepared in Exam-
ple 3 in a borate buffer (20 millimolar, pH 8.5) was then
prepared. Small aliquots of each dilution were placed on
Kapton ® disks and analyzed for their thermo-
chemiluminescence as in Example 2, and the data were
reduced and plotted by the same procedure. The resulting
plot is shown in FIG. 3. The coefficient of variation for
each point varied between 0.9% and 2.6%, while the
correlation coefficient of linear regression r=0.996.
These results again demonstrate the excellent reproduc-
ibility and linearity obtainable using the cyclodextrin
complexes of this invention.
We claim:
1. A thermochemiluminescent complex comprising an
adamantylideneadamantane 1,2-dioxetane and a cy-
clodextrin.
2. A thermochemiluminescent complex according to
claim 1, wherein said cyclodextrin is gamma-cyclodex-
trin.
3. A thermochemiluminescent complex according to
claim 1, wherein said adamantylideneadamantane 1,2-
dioxetane has the formula:
wherein R1 is selected from the group consisting of H,
Cl, Br, F, I, OH, NH2, OR
2 and NHR2, and wherein R2
is an aliphatic organic radical containing no more than
20 carbon atoms.
4. A thermochemiluminescent complex according to
claim 1, wherein said adamantylideneadamantane 1,2-
dioxetane has the formula:
5. A thermochemiluminescent complex according to
claim 4, wherein said cyclodextrin is gamma-cyclodex-
trin.
6. A method of immunoanalysis comprising encapsu-
lating an aqueous solution comprising a thermochemilu-
minescent complex of an adamantylideneadamantane 1,2-
dioxetane and a cyclodextrin within a microcapsule
having an exterior surface, said exterior surface bearing
an immunoreagent,
contacting said microcapsule in aqueous suspension
with an immunoreagent complementary to the
immunoreagent on said exterior surface, whereby an
immunocomplex is formed,
separating said immunocomplex from said aqueous
suspension,
heating said separated immunocomplex to a tempera-
ture at which said complex undergoes a thermo-
chemiluminescent reaction thereby emitting light,
and
determining the amount of light emitted in said ther-
mochemiluminescent reaction.
7. The method according to claim 6, wherein said
cyclodextrin is a gamma-cyclodextrin.
8. The method according to claim 6, wherein said
thermochemiluminescent adamantylideneadamantane
1,2-dioxetane has the formula:
wherein R1 is selected from thegroup consisting of H,
Cl, Br, F, I, OH, NH2, OR
2 and NHR2, and wherein R2
is an aliphatic organic radical containing no more than
20 carbon atoms.
9. The method according to claim 6, wherein said
thermochemiluminescent adamantylideneadamantane
1,2-dioxetane has the formula:
